Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 11,419 matching trials from the live ClinicalTrials.gov search.

Filters: Seattle, Washington Clear all

Conditions: Lennox Gastaut Syndrome (LGS)
Interventions: Placebo, Soticlestat; Drug
Lead sponsor: Takeda; Industry
Eligibility: 2 Years to 55 Years
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 24
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 17 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Placebo, Sotagliflozin; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 793 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 63
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Escondido, California + 55 more

Conditions: Hypogonadism, Late Onset Hypogonadism, Low Testosterone
Interventions: Dihydrotestosterone (0.7%) in hydroalcoholic gel; Drug
Lead sponsor: ASCEND Therapeutics; Industry
Eligibility: 55 Years to 80 Years · Male only
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 16
States / cities: Phoenix, Arizona • Torrance, California • Gainesville, Florida + 13 more

Conditions: Spinal Muscular Atrophy
Interventions: Nusinersen; Drug
Lead sponsor: Biogen; Industry
Eligibility: 0 Weeks to 6 Weeks
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 11
States / cities: Los Angeles, California • Sacramento, California • Aurora, Colorado + 8 more

Conditions: Hemophilia A
Interventions: Emicizumab, Factor VIII (FVIII); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 12 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 8
States / cities: Santa Monica, California • Washington D.C., District of Columbia • Gainesville, Florida + 5 more

Conditions: Adenocarcinoma of the Prostate
Interventions: IMC-A12 (Cixutumumab); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 3
States / cities: San Francisco, California • Portland, Oregon • Seattle, Washington

Conditions: Intra-amniotic Infection
Interventions: Not listed
Lead sponsor: ProteoGenix, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 21
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 16 more

Conditions: Recurrent Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions: 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, cisplatin, etoposide; Radiation · Drug
Lead sponsor: University of Washington; Other
Eligibility: Not listed
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Small Cell Lung Cancer
Interventions: Amrubicin; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 44
States / cities: Phoenix, Arizona • Lone Tree, Colorado • Ocala, Florida + 38 more

Conditions: Alcohol Risk Behaviors, Health Care Services Quality of Care
Interventions: Check Yourself App with Feedback; Behavioral
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 13 Years to 18 Years
Enrollment: 148 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 3
States / cities: Seattle, Washington

Conditions: Asthma
Interventions: Community Health Worker support; Behavioral
Lead sponsor: Public Health - Seattle and King County; Government
Eligibility: 18 Years to 65 Years
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Acute Alcoholic Hepatitis
Interventions: ELAD treatment, Standard of care (Control); Biological · Other
Lead sponsor: Vital Therapies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 35
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 25 more

Conditions: Platinum-resistant Ovarian Cancer, Platinum-resistant Fallopian Cancer, Platinum-resistant Peritoneal Cancer
Interventions: CRS-207, Epacadostat, Pembrolizumab; Biological · Drug
Lead sponsor: Aduro Biotech, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 10
States / cities: Scottsdale, Arizona • Stanford, California • Gainesville, Florida + 6 more

Conditions: Ankylosing Spondylitis
Interventions: adalimumab (D2E7), placebo; Biological
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 22
States / cities: Birmingham, Alabama • Mobile, Alabama • San Francisco, California + 18 more

Conditions: HIV Infections
Interventions: Raltegravir poloxamer film coated tablet, Raltegravir chewable tablet, Raltegravir oral granules for suspension (20 mg/mL); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 30 Days to 18 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 29
States / cities: Alhambra, California • La Jolla, California • Los Angeles, California + 19 more

Conditions: HER2/Neu Negative, Invasive Breast Carcinoma, Postmenopausal, Stage 0 Breast Cancer, Stage IA Breast Cancer
Interventions: Anastrozole, Exemestane, Laboratory Biomarker Analysis, Letrozole, Quality-of-Life Assessment, Questionnaire Administration, Tamoxifen Citrate, Toremifene Citrate; Drug · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 60 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Gastric Outlet Obstruction
Interventions: AXIOS(TM) Stent and Electrocautery Enhanced Delivery System; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: Boston, Massachusetts • Rochester, Minnesota • New York, New York + 2 more

Conditions: Carcinoma, Renal Cell
Interventions: Sorafenib (Nexavar, BAY43-9006), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 903 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 31
States / cities: Tucson, Arizona • Los Angeles, California • Sacramento, California + 27 more

Conditions: Mitral Valve Disease
Interventions: Transcatheter Mitral Valve Replacement; Device
Lead sponsor: Mayra Guerrero; Other
Eligibility: 22 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 15
States / cities: Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 9 more

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2+ Breast Cancer
Interventions: Trastuzumab (Herceptin), Pertuzumab, Echocardiography, Multigated Acquisition Scan, Mammography, Ultrasound, Magnetic Resonance Imaging, Biospecimen Collection, Questionnaire Administration; Biological · Procedure · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,524 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2037
U.S. locations: 698
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • Jonesboro, Arkansas + 537 more

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: VHB937, Placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 21
States / cities: La Jolla, California • Loma Linda, California • Los Angeles, California + 18 more

Conditions: Menopause Hot Flashes
Interventions: MT-8554 1mg, MT-8554 5mg, MT-8554 10mg, Placebo; Drug
Lead sponsor: Tanabe Pharma America, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 63
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 50 more

Conditions: Metastatic Non-Squamous Non-Small Cell Lung Cancer
Interventions: Nivolumab, Sitravatinib, Docetaxel; Biological · Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 577 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 133
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 109 more

Conditions: Ulcerative Colitis
Interventions: 75mg SHP647 (PF-00547659), 225mg SHP647 (PF-00547659); Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 66 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 29
States / cities: Scottsdale, Arizona • La Jolla, California • Orange, California + 26 more

Search by objective public record fields.

A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome

Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy

Study of DHT-Gel to Treat the Symptoms of Low Testosterone in Men 55-80

A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy

A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors

Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer

Non-invasive Test to Detect Intra-amniotic Infection in Women With Preterm Labor and Intact Amniotic Membranes

Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy

Web-Based Adolescent Motivational Enhancement Study

Home-Based Asthma Support and Education for Adults

Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure

Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer

Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis

Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents

Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer

AXIOS™ Gastroenterostomy for Gastric Outlet Obstruction IDE

Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer

Mitral Implantation of TRAnscatheter vaLves

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)

MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women

Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

Long-Term Safety Of PF-00547659 In Ulcerative Colitis